Mirum Pharmaceuticals’ Volixibat Trial Success Spurs $140 Price Target, 9.6% Share Jump
Mirum Pharmaceuticals’ volixibat met the primary endpoint in its Phase 2b PSC trial, delivering significant pruritus reductions. Morgan Stanley raised the price target to $140 (32% upside), lifting shares 9.6% to $105.79 and a 52-week high of $110.49, valuing the company at about $5.31 billion.
1. Volixibat Phase 2b Trial Results
Mirum Pharmaceuticals’ experimental oral agent, volixibat, met the primary endpoint in the VISTAS Phase 2b study for primary sclerosing cholangitis, demonstrating statistically significant and clinically meaningful reductions in severe pruritus among trial participants.
2. Analyst Price Target Increase
Following the positive trial data, Morgan Stanley raised its price target on Mirum stock from $130 to $140, implying a 32.34% upside from the then-current share price of $105.79 and reflecting increased confidence in the company’s liver disease pipeline.
3. Stock Market Reaction
Shares of Mirum climbed 9.59% to close at $105.79, reaching an intraday 52-week high of $110.49. The strong performance boosted the company’s market capitalization to approximately $5.31 billion.